ArticleIndian journal of nephrology2025
Retrospective Analysis of the Outcomes of Mycophenolate Therapy in Retarding the Progression of Immunoglobulin A Nephropathy (REMISSION IgA).
Article in Indian journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: IgA nephropathy (IgAN) is the most common form of glomerulonephritis globally, and a leading cause of end-stage kidney disease (ESKD). In India, IgAN accounts for 10-15% of kidney biopsies, often with nephrotic syndrome and renal impairment. Steroids are the mainstay of treatment, though the role of mycophenolate (MPA) is less explored. This study investigated the outcomes of MPA in IgAN. Materials and Methods: This retrospective study included patients ≥18 years old with biopsy-proven IgAN from January 1, 2010, to December 31, 2017, and eGFR >15 mL/min/1.73m Results: IgAN comprised 16.7% of kidney biopsies. The mean age of patients was 36.6±10.1 years, with 88.9% having hypertension. Over 60 months, eGFR decreased by 2 mL/min/1.73m Conclusion: MPA, in addition to steroids and ARBs, may help mitigate IgAN progression, though there were no differences in ESKD progression. Further randomized controlled trials are needed to validate the role of MPA in IgAN treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.